Journal
ATHEROSCLEROSIS
Volume 243, Issue 1, Pages 339-343Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2015.09.030
Keywords
Endocan; Inflammation; Atherosclerosis; Endothelial dysfunction; Cell adhesion
Funding
- MSD
- AstraZeneca
- Libytec
Ask authors/readers for more resources
Endothelial dysfunction is considered as an early change in atherogenesis. Raised levels of systemic inflammatory markers are associated with cardiovascular disease (CVD). Endocan (previously known as endothelial cell specific molecule-1, ESM-1), is a potential immunoinflammatory marker that may be linked to CVD. Endocan is released by vascular endothelial cells in several organs. Endocan may play an important role in regulating cell adhesion and raised plasma levels may reflect endothelial dysfunction. Endocan levels are elevated in conditions such as chronic kidney disease, renal transplant rejection, tumor progression and hypertension. Endocan is a potential inflammatory and CVD marker. Further studies are needed to assess the relevance of endocan in clinical practice. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available